[
  {
    "ts": null,
    "headline": "Barclays Initiates Coverage of Bristol-Myers Squibb (BMY) with Overweight Recommendation",
    "summary": "Barclays Initiates Coverage of Bristol-Myers Squibb (BMY) with Overweight Recommendation",
    "url": "https://finnhub.io/api/news?id=ac2742315680e14301b90c553dc5719e468990935391a652348451b2b87b319d",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771617847,
      "headline": "Barclays Initiates Coverage of Bristol-Myers Squibb (BMY) with Overweight Recommendation",
      "id": 139163484,
      "image": "",
      "related": "BMY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ac2742315680e14301b90c553dc5719e468990935391a652348451b2b87b319d"
    }
  },
  {
    "ts": null,
    "headline": "Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?",
    "summary": "BMY edges past MRK as generic headwinds bite, but new drug launches, cost cuts and a stronger 2026 outlook tilt the investment case in its favor.",
    "url": "https://finnhub.io/api/news?id=8fb0c318dd7273d4f986ab8f76fe50cdc438d4411227f1d342dc9689d425befe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771607100,
      "headline": "Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?",
      "id": 139163218,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMY edges past MRK as generic headwinds bite, but new drug launches, cost cuts and a stronger 2026 outlook tilt the investment case in its favor.",
      "url": "https://finnhub.io/api/news?id=8fb0c318dd7273d4f986ab8f76fe50cdc438d4411227f1d342dc9689d425befe"
    }
  },
  {
    "ts": null,
    "headline": "Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus",
    "summary": "PRTA posts a narrower year-over-year Q4 loss. Revenues miss estimates, as it outlines 2026 cash burn guidance and eyes key milestones from partners.",
    "url": "https://finnhub.io/api/news?id=53783120203016164cd9dd9500cec62dbbbecf49dce9070468ac4d2bc482cda0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771604820,
      "headline": "Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus",
      "id": 139162633,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRTA posts a narrower year-over-year Q4 loss. Revenues miss estimates, as it outlines 2026 cash burn guidance and eyes key milestones from partners.",
      "url": "https://finnhub.io/api/news?id=53783120203016164cd9dd9500cec62dbbbecf49dce9070468ac4d2bc482cda0"
    }
  },
  {
    "ts": null,
    "headline": "Barclays launches U.S. biopharma coverage with four preferred picks",
    "summary": "Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain investor attention in an uncertain macro backdrop, while naming Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY) and AbbVie Inc (NYSE:ABBV) as its top picks.",
    "url": "https://finnhub.io/api/news?id=24defe4374fd77db8c0683e041cc1dc376df6732125794a437ba7de5060bb531",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771592903,
      "headline": "Barclays launches U.S. biopharma coverage with four preferred picks",
      "id": 139159098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain investor attention in an uncertain macro backdrop, while naming Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY) and AbbVie Inc (NYSE:ABBV) as its top picks.",
      "url": "https://finnhub.io/api/news?id=24defe4374fd77db8c0683e041cc1dc376df6732125794a437ba7de5060bb531"
    }
  },
  {
    "ts": null,
    "headline": "Here Are Friday’s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More",
    "summary": "Pre-Market Stock Futures: Futures are trading lower as we wrap up the holiday-shortened week that gave us a little taste of just about everything. While Walmart posted results that beat expectations, its forward guidance and outlook fell short of Wall Street’s expectations, and the stock was down from the opening bell to the close. All ... Here Are Friday’s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More",
    "url": "https://finnhub.io/api/news?id=b83b4e394a5218c16e943180ffaeba77995521445b0579bf447ccffd97229ce7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771592369,
      "headline": "Here Are Friday’s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More",
      "id": 139159483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pre-Market Stock Futures: Futures are trading lower as we wrap up the holiday-shortened week that gave us a little taste of just about everything. While Walmart posted results that beat expectations, its forward guidance and outlook fell short of Wall Street’s expectations, and the stock was down from the opening bell to the close. All ... Here Are Friday’s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More",
      "url": "https://finnhub.io/api/news?id=b83b4e394a5218c16e943180ffaeba77995521445b0579bf447ccffd97229ce7"
    }
  },
  {
    "ts": null,
    "headline": "Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading Companies - Gilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More",
    "summary": "Technological advances and growing investments in stem cell research by private entities and governments enhance therapeutic production while reducing costs, fueling market growth and adoption Stem Cell and Regenerative Therapy Market Stem Cell and Regenerative Therapy Market Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The \"Stem Cell and Regenerative Therapy: Global Markets\" has been added to ResearchAndMarkets.com's offering. The global stem cell and regenerative therapy market is poised for subs",
    "url": "https://finnhub.io/api/news?id=e0ce4eae923c79ba0b12ed30f4b84d106a7d421f8459aee372e4cde2abf06447",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771590060,
      "headline": "Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading Companies - Gilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More",
      "id": 139159163,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Technological advances and growing investments in stem cell research by private entities and governments enhance therapeutic production while reducing costs, fueling market growth and adoption Stem Cell and Regenerative Therapy Market Stem Cell and Regenerative Therapy Market Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The \"Stem Cell and Regenerative Therapy: Global Markets\" has been added to ResearchAndMarkets.com's offering. The global stem cell and regenerative therapy market is poised for subs",
      "url": "https://finnhub.io/api/news?id=e0ce4eae923c79ba0b12ed30f4b84d106a7d421f8459aee372e4cde2abf06447"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Initiates Coverage On Bristol-Myers Squibb with Overweight Rating, Announces Price Target of $75",
    "summary": "Barclays  analyst Emily Field   initiates coverage on Bristol-Myers Squibb (NYSE:BMY) with a Overweight rating and announces Price Target of $75.",
    "url": "https://finnhub.io/api/news?id=3de0da9a8acb0cb8730c34a5b77ad97d2641755a5855671b8d98233de69256cf",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771584689,
      "headline": "Barclays Initiates Coverage On Bristol-Myers Squibb with Overweight Rating, Announces Price Target of $75",
      "id": 139160868,
      "image": "",
      "related": "BMY",
      "source": "Benzinga",
      "summary": "Barclays  analyst Emily Field   initiates coverage on Bristol-Myers Squibb (NYSE:BMY) with a Overweight rating and announces Price Target of $75.",
      "url": "https://finnhub.io/api/news?id=3de0da9a8acb0cb8730c34a5b77ad97d2641755a5855671b8d98233de69256cf"
    }
  }
]